Regulatory Infrastructure bill, drug price controls and the impact on...

Infrastructure bill, drug price controls and the impact on the pharma industry


Should the infrastructure bill be enacted, with “Aspects of H.R. 3” that include measures which peg U.S. prices of a number of prescription drugs to an international price index, it may have negative ramifications for the biopharmaceutical industry.

The direct price control measures in H.R. 3 go further and are of more immediate consequence to the biopharmaceutical industry.

It’s difficult to predict the precise series of responses by the biopharmaceutical industry to drug price containment actions subsumed under the pending infrastructure bill.

Read full article here

Latest news

Patient-Centric Clinical Trials And The Role Of A Travel Concierge

Many people find booking plane tickets, arranging road transportation and overnight lodging overwhelming. Add into that mix...

China forces insulin price cuts resulting in pullback for global pharma players

Xinhua, a Chinese news channel, commented on the price cut on insulin which was brought on by...

Aussie pharma CSL in talks to buy Swiss firm Vifor Pharma for USD 7B

CSL, the Australian giant, is in talks to buy Vifor Pharma in a deal that is valued...
- Advertisement -

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

Amgen’s KRAS drug gets early FDA approval for lung cancer with specific mutation

On Friday, the United States FDA (Food and Drug Administration) has authorized a medication of Amgen Biopharmaceutical in patients with NSCLC

You might also likeRELATED
Recommended to you